Suppr超能文献

C反应蛋白与白蛋白比值是一种经过验证的预后评分,可预测肾细胞癌手术患者的预后。

The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients.

作者信息

Guo Shengjie, He Xiaobo, Chen Qian, Yang Guangwei, Yao Kai, Dong Pei, Ye Yunlin, Chen Dong, Zhang Zhiling, Qin Zike, Liu Zhuowei, Xue Yunfei, Zhang Meng, Liu Ruiwu, Zhou Fangjian, Han Hui

机构信息

Department of Urology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, People's Republic of China.

Department of Medical Oncology, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.

出版信息

BMC Cancer. 2017 Mar 6;17(1):171. doi: 10.1186/s12885-017-3119-6.

Abstract

BACKGROUND

The preoperative C-reactive protein/Albumin (CRP/Alb) ratio has been shown to be valuable in predicting the prognosis of patients with certain cancers. The aim of our study is to explore its prognostic value in patients with renal cell carcinoma (RCC).

METHODS

A retrospective study was performed in 570 RCC patients underwent radical or partial nephrectomy including 541 patients who received full resection of localized (T1-3 N0/+ M0) RCC. The optimal cutoff value of CRP/Alb was determined by the receive operating characteristic (ROC) analysis. The impact of the CRP/Alb and other clinicopathological characteristics on overall survival (OS) and disease-free survival (DFS) was evaluated using the univariate and multivariate Cox regression analysis.

RESULTS

The optimal cutoff of CRP/Alb ratio was set at 0.08 according to the ROC analysis. Multivariate analysis indicated that CRP/Alb ratio was independently associated with OS of RCC patients underwent radical or partial nephrectomy (hazard ratio [HR]: 1.94; 95% confidence interval [95% CI]: 1.12-3.36; P = 0.018), and DFS of localized RCC patients underwent full resection (HR: 2.14; 95% CI: 1.22-3.75; P = 0.008).

CONCLUSION

Elevated CRP/Alb ratio was an independent prognostic indicator for poor OS in patients underwent radical or partial nephrectomy and DFS of localized RCC patients underwent full resection. Overall, CRP/Alb may help to identify patients with high relapse risk.

摘要

背景

术前C反应蛋白/白蛋白(CRP/Alb)比值已被证明在预测某些癌症患者的预后方面具有重要价值。本研究的目的是探讨其在肾细胞癌(RCC)患者中的预后价值。

方法

对570例行根治性或部分肾切除术的RCC患者进行回顾性研究,其中包括541例接受局限性(T1-3 N0/+ M0)RCC根治性切除的患者。通过接受者操作特征(ROC)分析确定CRP/Alb的最佳截断值。采用单因素和多因素Cox回归分析评估CRP/Alb及其他临床病理特征对总生存期(OS)和无病生存期(DFS)的影响。

结果

根据ROC分析,CRP/Alb比值的最佳截断值设定为0.08。多因素分析表明,CRP/Alb比值与接受根治性或部分肾切除术的RCC患者的OS独立相关(风险比[HR]:1.94;95%置信区间[95%CI]:1.12-3.36;P = 0.018),与接受根治性切除的局限性RCC患者的DFS独立相关(HR:2.14;95%CI:1.22-3.75;P = 0.008)。

结论

CRP/Alb比值升高是接受根治性或部分肾切除术患者OS不良以及接受根治性切除的局限性RCC患者DFS不良的独立预后指标。总体而言,CRP/Alb可能有助于识别复发风险高的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2934/5339967/2f9cc75ac0e4/12885_2017_3119_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验